Literature DB >> 22659452

Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis.

Shoichi Ihara1, Hiroshi Kida, Hisashi Arase, Lokesh P Tripathi, Yi-An Chen, Tetsuya Kimura, Mitsuhiro Yoshida, Yozo Kashiwa, Haruhiko Hirata, Reiko Fukamizu, Ruriko Inoue, Kana Hasegawa, Sho Goya, Ryo Takahashi, Toshiyuki Minami, Kazuyuki Tsujino, Mayumi Suzuki, Satoshi Kohmo, Koji Inoue, Izumi Nagatomo, Yoshito Takeda, Takashi Kijima, Kenji Mizuguchi, Isao Tachibana, Atsushi Kumanogoh.   

Abstract

Stat3 mediates a complex spectrum of cellular responses, including inflammation, cell proliferation, and apoptosis. Although evidence exists in support of a positive role for Stat3 in cancer, its role has remained somewhat controversial because of insufficient study of how its genetic deletion may affect carcinogenesis in various tissues. In this study, we show using epithelium-specific knockout mice (Stat3(Δ/Δ)) that Stat3 blunts rather than supports antitumor immunity in carcinogen-induced lung tumorigenesis. Although Stat3(Δ/Δ) mice did not show any lung defects in terms of proliferation, apoptosis, or angiogenesis, they exhibited reduced urethane-induced tumorigenesis and increased antitumor inflammation and natural killer (NK) cell immunity. Comparative microarray analysis revealed an increase in Stat3(Δ/Δ) tumors in proinflammatory chemokine production and a decrease in MHC class I antigen expression associated with NK cell recognition. Consistent with these findings, human non-small cell lung cancer (NSCLC) cells in which Stat3 was silenced displayed an enhancement of proinflammatory chemokine production, reduced expression of MHC class I antigen, and increased susceptibility to NK cell-mediated cytotoxicity. In addition, supernatants from Stat3-silenced NSCLC cells promoted monocyte migration. Collectively, our findings argue that Stat3 exerts an inhibitory effect on antitumor NK cell immunity in the setting of carcinogen-induced tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659452     DOI: 10.1158/0008-5472.CAN-11-4062

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Authors:  Stefani Spranger; Ayelet Sivan; Leticia Corrales; Thomas F Gajewski
Journal:  Adv Immunol       Date:  2016-01-22       Impact factor: 3.543

Review 2.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

3.  Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.

Authors:  Ya-Ting Wang; Jocelyn Chen; Chou-Wei Chang; Jayu Jen; Tzu-Yu Huang; Chun-Ming Chen; Roger Shen; Suh-Yuen Liang; I-Cheng Cheng; Shuenn-Chen Yang; Wu-Wei Lai; Kuang-Hung Cheng; Tao-Shih Hsieh; Ming-Zong Lai; Hung-Chi Cheng; Yi-Ching Wang; Ruey-Hwa Chen
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 4.  Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.

Authors:  Stefani Spranger
Journal:  Int Immunol       Date:  2016-03-17       Impact factor: 4.823

Review 5.  Impact of oncogenic pathways on evasion of antitumour immune responses.

Authors:  Stefani Spranger; Thomas F Gajewski
Journal:  Nat Rev Cancer       Date:  2018-01-12       Impact factor: 60.716

Review 6.  Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.

Authors:  Maria Saigi; Juan J Alburquerque-Bejar; Montse Sanchez-Cespedes
Journal:  Oncogene       Date:  2019-06-28       Impact factor: 9.867

7.  Integrated analysis identifies S100A16 as a potential prognostic marker for pancreatic cancer.

Authors:  Tian Chen; De-Meng Xia; Chao Qian; Shan-Rong Liu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 8.  Role of STAT3 in lung cancer.

Authors:  Pranabananda Dutta; Nafiseh Sabri; Jinghong Li; Willis X Li
Journal:  JAKSTAT       Date:  2015-01-20

9.  T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.

Authors:  Jonathan A Trujillo; Randy F Sweis; Riyue Bao; Jason J Luke
Journal:  Cancer Immunol Res       Date:  2018-09       Impact factor: 11.151

10.  Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer.

Authors:  Wang Zhang; Sumanta K Pal; Xueli Liu; Chunmei Yang; Sachin Allahabadi; Shaira Bhanji; Robert A Figlin; Hua Yu; Karen L Reckamp
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.